Nathan J. Dowden, President and COO of Entrada Therapeutics, Inc. ($TRDA), made two open market sales of common shares in the last year, totaling nearly $196,000. His most recent sale occurred on March 10, 2026. These transactions rank him 8,468th among 11,678 insiders by sale value, well below the average of $8.6 million across about six sales per insider. He reported no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 10, 2026 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | S | Common Stock | 11894 | $13.05 | 198,588.0000 | 41,462,567 | 5.65% | 0.03% |
| March 9, 2026 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | S | Common Stock | 3116 | $13.02 | 210,482.0000 | 41,462,567 | 1.46% | 0.01% |
| March 2, 2026 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 7223 | $11.66 | 227,636.0000 | 41,462,567 | 3.08% | 0.02% |
| March 3, 2026 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 14038 | $11.76 | 213,598.0000 | 41,462,567 | 6.17% | 0.03% |
| March 1, 2026 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | A | Stock Option (Right to Buy) | 83200 | $0.00 | 83,200.0000 | 41,462,567 | 9999.99% | 0.20% |
| March 1, 2026 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | A | Common Stock | 55800 | $0.00 | 234,859.0000 | 41,462,567 | 31.16% | 0.13% |
| Sept. 2, 2025 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 1746 | $5.43 | 179,059.0000 | 39,003,169 | 0.97% | 0.00% |
| March 1, 2025 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | A | Common Stock | 60800 | $0.00 | 185,949.0000 | 39,003,169 | 48.58% | 0.16% |
| March 3, 2025 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 5144 | $11.68 | 180,805.0000 | 39,003,169 | 2.77% | 0.01% |
| March 1, 2025 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | A | Stock Option (Right to Buy) | 90800 | $0.00 | 90,800.0000 | 39,003,169 | 9999.99% | 0.23% |
| Sept. 26, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | S | Common Stock | 847 | $16.00 | 125,149.0000 | 33,050,319 | 0.67% | 0.00% |
| Sept. 9, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | S | Common Stock | 1904 | $15.07 | 125,996.0000 | 33,050,319 | 1.49% | 0.01% |
| Sept. 6, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | S | Common Stock | 399 | $15.19 | 127,900.0000 | 33,050,319 | 0.31% | 0.00% |
| Sept. 5, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 171 | $15.13 | 128,299.0000 | 33,050,319 | 0.13% | 0.00% |
| Sept. 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 983 | $15.42 | 128,470.0000 | 33,050,319 | 0.76% | 0.00% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 15 | $17.70 | 129,453.0000 | 33,050,319 | 0.01% | 0.00% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 156 | $16.93 | 129,468.0000 | 33,050,319 | 0.12% | 0.00% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 483 | $15.76 | 129,624.0000 | 33,050,319 | 0.37% | 0.00% |
| Aug. 16, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | S | Common Stock | 26595 | $16.26 | 130,609.0000 | 33,050,319 | 16.92% | 0.08% |
| Aug. 16, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | M | Stock Option (Right to Buy) | 20000 | $0.00 | 64,831.0000 | 33,050,319 | 23.58% | 0.06% |
| Aug. 16, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | M | Common Stock | 20000 | $1.74 | 157,204.0000 | 33,050,319 | 14.58% | 0.06% |
| Aug. 16, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | S | Common Stock | 502 | $16.70 | 130,107.0000 | 33,050,319 | 0.38% | 0.00% |
| March 6, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | S | Common Stock | 1826 | $12.32 | 137,204.0000 | 33,050,319 | 1.31% | 0.01% |
| March 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 343 | $12.42 | 140,925.0000 | 33,050,319 | 0.24% | 0.00% |
| March 1, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | A | Common Stock | 60000 | $0.00 | 141,268.0000 | 33,050,319 | 73.83% | 0.18% |
| March 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 409 | $13.37 | 140,516.0000 | 33,050,319 | 0.29% | 0.00% |
| March 5, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | F | Common Stock | 1486 | $12.28 | 139,030.0000 | 33,050,319 | 1.06% | 0.00% |
| March 1, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | A | Stock Option (Right to Buy) | 50100 | $0.00 | 50,100.0000 | 33,050,319 | 9999.99% | 0.15% |
| March 1, 2024 | Entrada Therapeutics, Inc. | $TRDA | Dowden Nathan J | President & COO | A | Common Stock | 33100 | $0.00 | 81,268.0000 | 33,050,319 | 68.72% | 0.10% |